相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 技术资料
- 克隆性:
多克隆
- 抗体英文名:
InVivoMAb anti-mouse Ly6G
- 抗体名:
小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
- 规格:
5mg
小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
InVivoMAb anti-mouse Ly6G
InVivoMAb anti-mouse Ly6G
Bio X Cell抗体优势:
✔ 通过大规模的组织培养生产抗体,亲和层析法纯化抗体,
✔ 所有抗体均具有高纯度(>95%)、低内毒素(<2EU/mg),无防腐剂和稳定剂的特性,适用于体内临床前研究。
✔ 所有抗体可提供100mg甚至50g的大包装,性价比非常高。
■ Bio X Cell抗体应用
■ 热销抗体
| 抗原 | 应用 | 克隆号 | InVivoMab 目录号 |
InVivoPlus 目录号 |
| PD-1 | 体内PD-1/PD-L1信号封闭 | RMP1-14 | BE0146 | BP0146 |
| 体内PD-1/PD-L1信号封闭,体外PD-1中和,IHC(冰冻),IF,WB,FC | 29F.1A12 | BE0273 | BP0273 | |
| 体内PD-1/PD-L1信号封闭,体外PD-1中和,WB | J43 | BE0033-2 | BP0033-2 | |
| InVivo rat IgG2a isotype control, PD-1同型对照,排除Fc段与抗原的非特异性结合 | 2A3 | BE0089 | BP0089 | |
| PD-L1(B7-H1) | 体内PD-L1信号封闭,IF,IHC(冰冻),FC,WB | 10F.9G2 | BE0101 | BP0101 |
| InVivo rat IgG2b isotype control, PD-L1同型对照,排除Fc段与抗原的非特异性结合 | LTF-2 | BE0090 | BP0090 | |
| CTLA-4 | 体内 CTLA-4 中和,WB | 9D9 | BE0164 | BP0164 |
| 体内和体外中和CTLA-4,WB | 9H10 | BE0131 | BP0131 | |
| 体内和体外中和CTLA-4,FC,WB | UC10- 4F10-11 |
BE0032 | BP0032 | |
| NK1.1 | 体内NK细胞去除,FC | PK136 | BE0036 | BP0036 |
| CD3ε | 体内T细胞去除,体外T细胞刺激/激活,IF,FC,WB, | 145-2C11 | BE0001-1 | BP0001-1 |
| CD4 | 体内CD4+T细胞去除,FC,WB | GK1.5 | BE0003-1 | BP0003-1 |
| CD8α | 体内CD8+T细胞去除,IF,FC,WB | 53-6.7 | BE0004-1 | BP0004-1 |
| CD25 (IL-2Rα) | 体内调节T细胞去除,FC | PC-61.5.3 | BE0012 | BP0012 |
| CD28 | 体内CD8封闭,体外T细胞刺激/激活 | 37.51 | BE0015-1 | / |
| 体外T细胞刺激/激活 | PV-1 | BE0015-5 | / | |
| CSF1R (CD115) | 体内巨噬细胞去除,体外CSF-R1中和,体内单核细胞去除, FC,WB | AFS98 | BE0213 | BP0213 |
| IL-4 | 体内IL-4中和,体外IL-4中和,体内IL-4受体刺激(as a complex with IL-4) FC,WB |
11B11 | BE0045 | BP0045 |
| IFNγ (interferon gamma) |
体内IFNγ中和,体外IFNγ中和,ELISPOT,FC,WB | XMG1.2 | BE0055 | BP0055 |
| Ly6G | 体内中性粒细胞耗竭,体内MDSC耗尽, IF,IHC(石蜡或冰冻),FC | 1A8 | BE0075-1 | BP0075-1 |
| Ly6G/Ly6C (Gr-1) | 体内Gr-1+骨髓细胞去除,IHC(石蜡或冰冻),FC | RB6-8C5 | BE0075 | BP0075 |
| IFNAR-1 | 体内IFNAR-1阻断,体外IFNAR-1阻断,WB | MAR1-5A3 | BE0241 | BP0241 |
■ InVivoMab VS InVivoPlus
| - | InVivoMab | InVivoPlus |
| 纯度 | >95% | >95% |
| 蛋白完整性 | √(SDS-PAGE) | √(SDS-PAGE) |
| 内毒素浓度 | <2EU/mg | <1EU/mg |
| 有效性验证(WB/FC/ELISA) | √ | |
| 蛋白聚集物<5% | √ | |
| 小鼠病原体测试 | √ | |
| 无叠氮化物和载体蛋白 | √ | √ |
| 大批量生产 | √ | √ |
| 适用体内研究 | √ | √ |
| 目录号 | 以BE开头 | 以BP开头 |
InVivoPlusTM 系列抗体非常适用于高灵敏性实验以及用活细胞或整个动物进行各种功能测定的体内研究,可加快您的研究进展。
■ 热销同型对照和InVivoPure抗体稀释Buffer
| 产品类型 | 品名 | 用途 | InVivoMab 目录号 |
InVivoPlus 目录号 |
| 部分热卖同型 对照 |
InVivoMab rat IgG2a isotype control | 排除一抗的Fc段与 抗原的非特异性结合, 使实验结果更加严谨, 有助于您发表高分论文 |
BE0089 | BP0089 |
| InVivoMab rat IgG2b isotype control | BE0090 | BP0090 | ||
| InVivoMab mouse IgG1 isotype control | BE0083 | BP0083 | ||
| InVivoMAb human IgG1 isotype control | BE0297 | BP0297 | ||
| InVivoPlus rat IgG2a isotype control | BE0089 | BP0089 | ||
| InVivoMab mouse IgG2a isotype control | BE0085 | BP0085 | ||
| InVivoMabrat IgG1 isotype control | BE0088 | BP0088 | ||
| InVivoPlus mouse IgG1 isotype control | BE0083 | BP0083 | ||
| InVivoMAb polyclonal Armenian hamster IgG | BE0091 | BP0091 | ||
| 抗体稀释Buffer | InVivoPure pH 7.0 Dilution Buffer | 官方指定抗体稀释 buffer,确保抗体使用 性能,加快您的实验进展 |
IP0070 | / |
| InVivoPure pH 6.5 Dilution Buffer | IP0065 | / |
✔ 为了加快您实验进度,确保实验结果的准确性,建议您搭配使用Bio X Cell一抗对应的同型对照(排除一抗的非特异性结合)和InVivoPure抗体稀释缓冲液。
About InVivoMAb anti-mouse Ly6G
The 1A8 monoclonal antibody reacts with mouse Ly6G. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Ly6G is expressed differentially during development by cells in the myeloid lineage including monocytes, macrophages, granulocytes, and neutrophils. Monocytes typically express Ly6G transiently during development while mature granulocytes and peripheral neutrophils retain expression making Ly6G a good cell surface marker for these populations. Unlike the RB6-8C5 antibody, the 1A8 antibody reacts specifically with mouse Ly6G with no reported cross reactivity with Ly6C.InVivoMAb anti-mouse Ly6G Specifications
| Isotype | Rat IgG2a, κ |
| Recommended Isotype Control(s) | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(BE0089) |
| Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
| Immunogen | EL4J cells transfected with Ly6G |
| Reported Applications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from tissue culture supernatant in an animal free facility |
| Purification | Protein G |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| RRID | AB_1107721 |
| Molecular Weight | 150 kDa |
Application References
InVivoMAb anti-mouse Ly6G (Clone: 1A8)
Davis, R. W. t., et al. (2018). "Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy." Photochem Photobiol. PubMed Inflammatory cells, most especially neutrophils, can be a necessary component of the antitumor activity occurring after administration of photodynamic therapy. Generation of neutrophil responses has been suggested to be particularly important in instances when the delivered photodynamic therapy (PDT) dose is insufficient. In these cases, the release of neutrophil granules and engagement of antitumor immunity may play an important role in eliminating residual disease. Herein, we utilize in vivo imaging of luminol chemiluminescence to noninvasively monitor neutrophil activation after PDT administration. Studies were performed in the AB12 murine model of mesothelioma, treated with Photofrin-PDT. Luminol-generated chemiluminescence increased transiently 1 h after PDT, followed by a subsequent decrease at 4 h after PDT. The production of luminol signal was not associated with the influx of Ly6G(+) cells, but was related to oxidative burst, as an indicator of neutrophil function. Most importantly, greater levels of luminol chemiluminescence 1 h after PDT were prognostic of a complete response at 90 days after PDT. Taken together, this research supports an important role for early activity by Ly6G(+) cells in the generation of long-term PDT responses in mesothelioma, and it points to luminol chemiluminescence as a potentially useful approach for preclinical monitoring of neutrophil activation by PDT.风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
技术资料暂无技术资料 索取技术资料
小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
¥5600









